(BIM) Biomerieux - Ratings and Ratios
Culture, PCR, AST, Sepsis, Software
Description: BIM Biomerieux
bioMérieux S.A. is a leading developer and marketer of in vitro diagnostic solutions for infectious diseases, operating globally across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The companys product portfolio includes a range of innovative solutions, such as chromogen culture media, biochemical tests, air and water monitoring systems, and mass spectrometry systems, designed to support diagnosis and clinical decision-making.
From a business perspective, bioMérieux S.A. has demonstrated a strong track record of growth, driven by its commitment to innovation and strategic partnerships. Key performance indicators (KPIs) such as revenue growth rate, return on equity (RoE) of 18.00%, and a forward price-to-earnings ratio (P/E) of 25.77 suggest a solid financial foundation. The companys market capitalization stands at €14,033.55M, indicating a significant presence in the biotechnology sector.
To further evaluate the companys prospects, it is essential to monitor KPIs such as research and development (R&D) expenditure as a percentage of revenue, sales growth in key regions, and the success rate of new product launches. Additionally, metrics like customer satisfaction ratings, product adoption rates, and the effectiveness of its partnerships with companies like Boehringer Ingelheim and Evotec will be crucial in assessing bioMérieux S.A.s competitive position and future growth potential.
From a strategic perspective, bioMérieux S.A.s focus on developing innovative diagnostic solutions for infectious diseases aligns with the growing demand for precision medicine and targeted therapies. As the company continues to expand its product portfolio and strengthen its global presence, investors should closely monitor its progress in key markets, as well as its ability to drive growth through strategic partnerships and investments in R&D.
BIM Stock Overview
| Market Cap in USD | 15,916m |
| Sub-Industry | Biotechnology |
| IPO / Inception |
BIM Stock Ratings
| Growth Rating | 61.8% |
| Fundamental | 79.1% |
| Dividend Rating | 55.5% |
| Return 12m vs S&P 500 | -10.6% |
| Analyst Rating | - |
BIM Dividends
| Dividend Yield 12m | 0.79% |
| Yield on Cost 5y | 0.76% |
| Annual Growth 5y | 34.94% |
| Payout Consistency | 95.8% |
| Payout Ratio | 28.4% |
BIM Growth Ratios
| Growth Correlation 3m | -12.5% |
| Growth Correlation 12m | 86.9% |
| Growth Correlation 5y | 10.8% |
| CAGR 5y | 13.16% |
| CAGR/Max DD 3y | 0.84 |
| CAGR/Mean DD 3y | 2.59 |
| Sharpe Ratio 12m | 0.81 |
| Alpha | -0.61 |
| Beta | 0.237 |
| Volatility | 22.32% |
| Current Volume | 141.8k |
| Average Volume 20d | 83.9k |
| Stop Loss | 111 (-3.1%) |
| Signal | -1.08 |
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (660.4m TTM) > 0 and > 6% of Revenue (6% = 408.5m TTM) |
| FCFTA 0.11 (>2.0%) and ΔFCFTA 8.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 18.68% (prev 19.94%; Δ -1.26pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 1.28b > Net Income 660.4m (YES >=105%, WARN >=100%) |
| Net Debt (125.9m) to EBITDA (1.53b) ratio: 0.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.27 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (118.9m) change vs 12m ago -0.04% (target <= -2.0% for YES) |
| Gross Margin 54.80% (prev 51.83%; Δ 2.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 128.2% (prev 106.6%; Δ 21.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 40.01 (EBITDA TTM 1.53b / Interest Expense TTM 25.9m) >= 6 (WARN >= 3) |
Altman Z'' 2.93
| (A) 0.24 = (Total Current Assets 2.28b - Total Current Liabilities 1.00b) / Total Assets 5.37b |
| (B) 0.03 = Retained Earnings (Balance) 161.0m / Total Assets 5.37b |
| (C) 0.19 = EBIT TTM 1.03b / Avg Total Assets 5.31b |
| (D) -0.03 = Book Value of Equity -48.6m / Total Liabilities 1.43b |
| Total Rating: 2.93 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 79.05
| 1. Piotroski 9.50pt = 4.50 |
| 2. FCF Yield 4.32% = 2.16 |
| 3. FCF Margin 8.75% = 2.19 |
| 4. Debt/Equity 0.15 = 2.49 |
| 5. Debt/Ebitda 0.39 = 2.38 |
| 6. ROIC - WACC 11.29% = 12.50 |
| 7. RoE 16.76% = 1.40 |
| 8. Rev. Trend 19.94% = 1.00 |
| 9. Rev. CAGR 5.17% = 0.65 |
| 10. EPS Trend -8.43% = -0.21 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BIM shares?
Over the past week, the price has changed by +0.53%, over one month by -9.05%, over three months by -5.22% and over the past year by +6.31%.
Is Biomerieux a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIM is around 107.89 EUR . This means that BIM is currently overvalued and has a potential downside of -5.77%.
Is BIM a buy, sell or hold?
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.3 | 8.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 118.3 | 3.3% |
BIM Fundamental Data Overview
Market Cap EUR = 13.57b (13.57b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 380.5m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 36.3091
P/E Forward = 24.1546
P/S = 3.2931
P/B = 3.4815
P/EG = 1.9313
Beta = 0.465
Revenue TTM = 6.81b EUR
EBIT TTM = 1.03b EUR
EBITDA TTM = 1.53b EUR
Long Term Debt = 423.5m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 172.1m EUR (from shortTermDebt, last quarter)
Debt = 595.6m EUR (Calculated: Short Term 172.1m + Long Term 423.5m)
Net Debt = 125.9m EUR (from netDebt column, last quarter)
Enterprise Value = 13.79b EUR (13.57b + Debt 595.6m - CCE 380.5m)
Interest Coverage Ratio = 40.01 (Ebit TTM 1.03b / Interest Expense TTM 25.9m)
FCF Yield = 4.32% (FCF TTM 595.8m / Enterprise Value 13.79b)
FCF Margin = 8.75% (FCF TTM 595.8m / Revenue TTM 6.81b)
Net Margin = 9.70% (Net Income TTM 660.4m / Revenue TTM 6.81b)
Gross Margin = 54.80% ((Revenue TTM 6.81b - Cost of Revenue TTM 3.08b) / Revenue TTM)
Tobins Q-Ratio = -283.7 (set to none) (Enterprise Value 13.79b / Book Value Of Equity -48.6m)
Interest Expense / Debt = 1.26% (Interest Expense 7.50m / Debt 595.6m)
Taxrate = 26.64% (154.3m / 579.3m)
NOPAT = 758.8m (EBIT 1.03b * (1 - 26.64%))
Current Ratio = 2.27 (Total Current Assets 2.28b / Total Current Liabilities 1.00b)
Debt / Equity = 0.15 (Debt 595.6m / last Quarter total Stockholder Equity 3.93b)
Debt / EBITDA = 0.39 (Net Debt 125.9m / EBITDA 1.53b)
Debt / FCF = 1.00 (Debt 595.6m / FCF TTM 595.8m)
Total Stockholder Equity = 3.94b (last 4 quarters mean)
RoA = 12.31% (Net Income 660.4m, Total Assets 5.37b )
RoE = 16.76% (Net Income TTM 660.4m / Total Stockholder Equity 3.94b)
RoCE = 23.71% (Ebit 1.03b / (Equity 3.94b + L.T.Debt 423.5m))
RoIC = 17.93% (NOPAT 758.8m / Invested Capital 4.23b)
WACC = 6.64% (E(13.57b)/V(14.17b) * Re(6.89%)) + (D(595.6m)/V(14.17b) * Rd(1.26%) * (1-Tc(0.27)))
Shares Correlation 3-Years: -7.75 | Cagr: -0.01%
Discount Rate = 6.89% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈413.0m ; Y1≈509.5m ; Y5≈869.4m
Fair Price DCF = 125.4 (DCF Value 14.79b / Shares Outstanding 117.9m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 19.94 | Revenue CAGR: 5.17%
Rev Growth-of-Growth: -37.00
EPS Correlation: -8.43 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 168.9